
ç·æ¥é¿åŠè¬ãã¢ãŒãã³ã°ã¢ãã¿ãŒãã«ã
ã2026幎2æãªã©ã€ãã
ç·æ¥é¿åŠæ³ïŒECïŒEmergency ContraceptionïŒã§çšããããç·æ¥é¿åŠè¬ïŒã¢ãã¿ãŒãã«ïŒã«ã€ããŠãå°ããŸãšããŠããããšæããŸãã
ïŒïŒã©ããã£ããšãã«ç·æ¥é¿åŠãå¿ èŠã«ãªãã®ãïŒ
ãé¿åŠãããŠããªã
ãæ§äº€äžã«ã³ã³ããŒã ãç Žãããã
ãºã¬ããã䜿çšãããŠããªãã£ããããå Žå
ãè£å€å°ç²Ÿ
ãé¿åŠè¬ã®æçšãå¿ããå Žå
ïŒïŒæ¥ä»¥äžç¶ããŠæçšãå¿ããŠããïŒ
ãåå®®å é¿åŠåšå ·ãé©åã«äœ¿çšãããªãã£ãå Žå
ãæ§çæŽè¡ã«ãã被害
äž»ã«ãããã£ãããšãæããããŸããããã¯ãç·æ¥é¿åŠå€æ¥ãå蚺ããçç±ãšããŠã¯ããè£å€å°ç²Ÿããã°å€§äžå€«ããšãã£ãé¿åŠã«å¯Ÿãã誀ã£ãèãæ¹ããã³ã³ããŒã ã¯ã€ããŠãããã©èª€ã£ãäœ¿çšæ¹æ³ããããããããã¯å€±æããŠããŸã£ããšããã±ãŒã¹ãå€ãããã§ãã
ç·æ¥é¿åŠãå¿ èŠã«ãªãéçšã¯ãå¹Œå æã»å ç«¥æã»ææ¥æã«ãããäžååãªæ§æè²ãšããèŠå ãããã®ããªãšæããŸãã
æ§æè²ãå çãä¿è·è ãèªãããã«ãããããªãã®æ¹æ³ãšèŠæãå¿ èŠã«ãªããŸãããçµµæ¬ãæ¬ãçšããã°åœäººéãèœåçã«æ å ±ãåŸãããšãã§ããã®ã§äŸ¿å©ã§ãã
ãæ§æè²çµµæ¬ã»æ¬ãã«é¢ããæ
å ±ããŸãšãŸã£ãããããããµã€ããããã®ã§æ²èŒããŠãããŸããäžåºŠã芧ãã ãã
ïŒãå®¶åºã§ã§ããæ§æè²ãµã€ããåœè²ãïŒãâãâ
ç§ã¯ç·ãªã®ã§ã¢ãã¿ãŒãã«ãæçšããæ°æã¡ãå®éã«æçšããäººã®æ°æã¡ãäžçäœéšããããšã¯ã§ããŸãããããnoteãã§ã®æ²èŒãããããªã€ã¿ãããã®æžãããŠãããã®å°èª¬ã¯ãã®å Žé¢æ¯ã®æ°æã¡ã颚æ¯ãæåãããŠããŠå¿æ ãããäŒãã£ãŠããŸããã
ïŒïŒé¿åŠè¬ãšããŠã¯ã©ããã£ããã®ãããã®ãïŒ
ä»åã¯ç·æ¥é¿åŠè¬ã«ã€ããŠãŸãšããŠãããããšæããŸãã®ã§ãé¿åŠè¬ã«ã€ããŠã¯è»œãã ãè§ŠããŠãããŸãã
2.1 çµå£é¿åŠè¬ïŒäœçšéçµå£é¿åŠè¬ïŒOCãOral Contraceptives)
OCã«ã¯åæãããåµèãã«ã¢ã³ïŒãšã¹ããã²ã³ïŒãšé»äœãã«ã¢ã³ïŒããã²ã¹ããã³ïŒãå«ãŸããŠããŸãã
äžè¬çã«ã¯æçµåçå矀ïŒPMSïŒã®æ²»çã§çšããããããšãå€ãã§ãããé¿åŠè¬ãšããŠçšãããããã®ããããŸãã
PMSã®ããã®OCïŒãã®å Žåäžè¬çã«ã¯LEPãlow dose progestinããšåŒã°ããïŒã¯ä¿éºé©çšã§ãããé¿åŠè¬ãšããŠã®è£œåïŒããªãã¥ã©ãŒãããŒããã³ãã©ãã«ãã£ãŒãŠããã¡ãã¯ãŒã«ãã¢ã³ãžã¥ãã»ã©ãŒãã¿ããã¢ã«ãã³ïŒã¯èªè²»èšºçãšãªããŸãã
â ãäžçžæ§OCïŒ
é»äœãã«ã¢ã³ãšåµèãã«ã¢ã³ã®å²åãåžžã«äžå®
ãããŒããã³21ãããŒããã³28ããã¡ãã¯ãŒã«21ããã¡ãã¯ãŒã«28ã
â ãäžçžæ§OCïŒ
é»äœãã«ã¢ã³éãæ®µéçã«å¢ããŠãã
ïŒçççåšæã«è¿ã¥ããŠããïŒ
ãã¢ã³ãžã¥21ãã¢ã³ãžã¥28ãããªãã¥ã©ãŒ21ãããªãã¥ã©ãŒ28ãã©ãã«ãã£ãŒãŠ21ãã©ãã«ãã£ãŒãŠ28ã
ïŒ21ã®å Žåã7æ¥éã®äŒè¬ãããã28ã®å Žåã7æ¥éåœè¬ãæçšããïŒ
â»ã©ã¡ãã®è£œå€ã§ãé¿åŠå¹æã«å€§ããªå·®ã¯ãªããšèšãããŠããŸãã

å¯äœçšãšããŠã¯ãã©ããã£ããã®ãããã®ãïŒ
ïŒïŒæªå¿ã»åå
ïŒïŒä¹³æ¿ç·æºæã»ä¹³æ¿ç
ïŒïŒé çã»çé ç
ïŒïŒäžè
¹éšç
LEPæçšã§ã¯ã宿çãªæçšã倧åã«ãªã£ãŠããŸãããæçšéå§3ãæããããŸã§ã¯ãããã®å¯äœçšãåºãããææãç¶ããŸãã
åšæãé²ããšãããã®å¯äœçšã®å€ãã¯æ¶å€±ããããšãèŠããŠããããšã倧åã§ãã
2.2 åå®®å é¿åŠçšå ·
IUSïŒåå®®å é¿åŠã·ã¹ãã ïŒã¯é»äœãã«ã¢ã³ãæŸåºãåå®®å èã®è¥åãé²ãå粟åµã®çåºãé²ããŸããã¬ããã«ã²ã¹ãã¬ã«ãå«ãã ãã¬ãŒãã·ã¹ãã 52mg®ã¯ãçŽ5幎éæç¶çã«æŸåºãç¶ããŸãã
é ä»å IUDïŒåå®®å é¿åŠçšå ·ïŒã¯é ã€ãªã³ã®åãã§å粟ãšçåºãé²ããïŒå¹ŽçšåºŠé¿åŠå¹æãæç¶ãããšãããŠããŸãã

é
ä»å IUDã¯ãé
ã€ãªã³ã®ç²Ÿåã«å¯ŸããçŽæ¥äœçšã«ãããå粟åã®ç²Ÿåã®éåèœåãäœäžãããŠå粟ãé»å®³ããŸãã
ãã§ã«å粟ãèµ·ããŠããå Žåã§ããçåºé»å®³äœçšãããããå粟åããã³å粟åŸã®äž¡æ¹ã«å¹æããããšèšãããŠããŸãã
ããããåŠåš çµéšããªãå Žåã«ã¯åå®®å£ãçãæ¿å ¥ãå°é£ãšãèšãããŠããŸãã
2.3 ã³ã³ããŒã
èããŽã ãããã¹ã«ãã¶ããŠäœ¿çšãããæ§ææçäºé²ã«ã¯å¹æçã
2.4 é¿åŠæè¡
åµç®¡ããã°ã
ã»ãã«ã¯ãåºç€äœæž©ã女æ§èªèº«ã枬å®ãããšããæ¹æ³ããããŸããã確å®ãªé¿åŠæ¹æ³ã§ã¯ãªããããäžé©åã§ãããšèšãããŠããŸãã
ãã®ãããã®å 容ã«ã€ããŠã¯ããã€ãšã«è¬åã®ãé¿åŠã®ã¹ã¹ã¡ãã®ããŒãžã«è©³ããæžããŠãããŸããã

ïŒïŒé¿åŠå€±æçïŒåŠåš çïŒã¯ã©ãããããªã®ãïŒ
ããã€ãæç®ãã§ãŠããããã§ãããã²ãšã€ããã¯ã¢ããããŠã¿ãããšæããŸãã
Contraceptive failure in the United States,Contraception.83(5):397-404,2011(PMID 21477680 )
ç±³åœã«ãããé¿åŠã®å€±æã«ã€ããŠãŸãšãããããã®ã«ãªããŸãããæç®ã®äžã®è¡šã®å å®¹ãæ¥æ¬èªã§ãŸãšãããšæ¬¡ã®ããã«ãªããŸãã

衚ã¯åŠåš çïŒé¿åŠå€±æçïŒã瀺ããŠããã®ã§ãäžè¬çãªäœ¿çšã§ã¯ã³ã³ããŒã ãåºç€äœæž©ã«ãããªãºã æ³ã®é¿åŠå¹æãä»ã®é¿åŠæ¹æ³ãšæ¯ã¹ãŠäœãããšãããããŸãã
ãã®è³æã®äžã®çµµãããããããã£ãã®ã§èŒããŠãããŸãïŒäžããé¿åŠå¹æã®é«ãé ã«ãªã£ãŠããŸãïŒã

ïŒïŒç·æ¥é¿åŠè¬ãåŠæ¹ããŠãããã«ã¯ã©ãã«è¡ã£ããããã®ãïŒ
2026幎2æ2æ¥ããèŠæå°å»è¬åã§ãããç·æ¥é¿åŠè¬ããè¬å±ããã©ãã°ã¹ãã¢ãªã©ã§è³Œå ¥ã§ããããã«ãªããŸããããã¡ãããåŸæ¥ã©ãããç£å©Šäººç§ããå蚺ããŠãè¬ãåããšããšããéžæè¢ãæ®ãããŠããŸãã
ïŒïŒè¬å±ã§è³Œå ¥ããå Žå
2026幎2æ2æ¥ãããäžå®ã®èŠä»¶ãæºãããè¬å±ã»ãã©ãã°ã¹ãã¢ã§ãåŠæ¹ç®ãªãã§ç·æ¥é¿åŠè¬ïŒã¢ãã¿ãŒãã«ïŒããã«ã¬ãããçŽæ¥è³Œå ¥å¯èœã«ãªããŸããã
販売ãããè¬: ãã«ã¬ãïŒäžè¬åïŒã¬ããã«ã²ã¹ãã¬ã«1.5mgïŒã
äŸ¡æ Œ: 1é 7480åïŒçšèŸŒïŒã
è³Œå ¥æ¹æ³: è¬å€åž«ã®å¯Ÿé¢è²©å£²ãå¿ èŠã
æçšã«ãŒã«: è¬å€åž«ã®ç®ã®åã§æçšããå¿ èŠãããã
察象è : 幎霢å¶éã¯ãªãããè³Œå ¥æã¯è¬å€åž«ã®ç¢ºèªãå¿ èŠã
åºèã®æ¢ãæ¹: åçåŽåçããèŠæå°å»è¬åã§ããç·æ¥é¿åŠè¬ã®è²©å£²ãå¯èœãªè¬å±çã®äžèЧããå ¬éããŠããŸãããä»åŸæŽã«åºèæ°ã¯å¢ããŠãããã®ãšäºæ³ãããŸãã
https://www.mhlw.go.jp/stf/kinnkyuuhininnyaku_00005.html
詳ããã¯ããã«ã¬ãé ãã®ãµã€ãã§ç¢ºèª
è¬å±ã«é»è©±ããåã«ãããã«ã¬ããè³Œå ¥ã»æçšã®æµãããäžèªããŠããããšãããããããŸãã
ç±³åœã§ã®ç·æ¥é¿åŠè¬è²©å£²ç¶æ³ã«ã€ããŠãå¥ã®ããã°ã§èšèŒããŠããŸããè¬å€åž«ãé¢ãã£ãŠããå·ãšé¢ãã£ãŠããªãå·ã§ã®ç¥èã»å¯Ÿå¿ã®å·®ã«ã泚ç®ããŠãã ããã
2ïŒç é¢ãå蚺ããå Žå
åçåŽåçã®ããŒã ããŒãžäžã§ãç·æ¥é¿åŠã«ããã察é¢èšºçãå¯èœãªç£å©Šäººç§å»çæ©é¢çã®äžèЧãäœæãå ¬è¡šããŠããŸããïŒhttps://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000186912_00002.htmlïŒ
éœéåºçããšã«åããããŠããããã¡ã€ã«ã¯PDFãšãªã£ãŠããŸãã
ãŸããä»åŸããªã³ã©ã€ã³èšºçãè¡ãå»çæ©é¢ãç·æ¥é¿åŠè¬ã®èª¿å€ãåããè¬å±ã®äžèЧããã®ãµã€ãã«æ²èŒãããŠããäºå®ãšãªã£ãŠããŸãã

ããã«ãæžãããŠããŸãããåŠæ¹ãã¹ããã©ããã®å€æã¯ç¶æ³ãèŽåãå»åž«ã倿ããå¿ èŠããããããé©åãªå»çæ©é¢ã®å蚺ãããããããŠããŸãã
ãã®ãã¡ã€ã«ã¯PDFãšãªã£ãŠããããããã®ãã¡ã€ã«ããæ¢ãéã«ã¯ãèªåãäœãã§ããå°åã®ååãããã¯ç é¢åããæ€çŽ¢ïŒCtrl+FïŒããããšã«ãªããŸãã

ãŸãããPDF â Wordã§èªã¿èŸŒã â Exelã«ã³ããããšããæ¹æ³ã§Exel倿ãã§ããã®ã§å€æããŠGooglemapã«èªã¿èŸŒãã§èŠèŠçã«ãããããããããšããæ¹æ³ããããããããŸããã詳ããããæ¹ã¯äžã®ãªã³ã¯ã«
äŸãã°åæµ·éã§äžèšæäœãè¡ã£ãŠã¿ããšãããªæãã§è¡šç€ºãããŸããå»çæ©é¢ã®äœçœ®ãšãã¡ã€ã«ã«ä¿åãããŠããæ å ±ãäžç®ã§ã¿ããŠããããããã§ãã

ãŸããã©ããããã®é »åºŠã§å»çæ©é¢ã®æŽæ°ãè¡ãããŠãããã¯ããããŸãããããã¡ãã®ãµã€ãã§ãå»çæ©é¢ã®æ€çŽ¢ãå¯èœãšãªã£ãŠããŸãïŒæ€çŽ¢çµæã¯ã¿ãããã§ãïŒã
ïŒïŒãªã³ã©ã€ã³èšºç
æµ·å€ããã®èŒžå
¥è¬ã®è»¢å£²ãè²æž¡ãæ£èŠãããŠããäžããªã³ã©ã€ã³èšºçãå®å
šãã€é©åã«æ®åããŠããããã«ã¯ãã«ãŒã«ã®æŽåãå¿
èŠã§ããããšãããããªã³ã©ã€ã³èšºçã®é©åãªå®æœã«é¢ããæéããå¹³æ30幎3ææ«ã«çºåºãããå°ãªããšã1幎ã«1åä»¥äžæŽæ°ãããããšãšãªã£ãŠããŸããã
ãã®åŸãããªã³ã©ã€ã³èšºçã®é©åãªå®æœã«é¢ããæéã®èŠçŽãã«é¢ããæ€èšäŒãã«ãããŠïŒåºŠã»ã©é¿åŠã«é¢ãã話é¡ãåãäžããããŠããŸãã
2019幎3æ29æ¥
å蚺察é¢èšºçã®äŸå€ïŒãªã³ã©ã€ã³èšºçã«ãããç·æ¥é¿åŠã«ã€ããŠïŒ
2019幎4æ24æ¥
ãªã³ã©ã€ã³èšºçã§ç·æ¥é¿åŠãè¡ãå Žåã®èŠä»¶ã«ã€ããŠ
2019幎5æ31æ¥
ãªã³ã©ã€ã³èšºçã§ç·æ¥é¿åŠãè¡ãå Žåã®èŠä»¶çã«ã€ããŠ
ãã®äžã§ã¯å®æã«åŠæ¹ã§ãããšæªçšã«ã€ãªãããšããã¯ãŒããããåºãŠããŠããŸããããããã§ããæªçšãšã¯ã©ããã£ãããšãæããŠããã®ã§ãããã?
ã€ããªã¯ãã¡ã«ã«ãªãããã販売ã§è»¢å£²ãããŠããŸãããšã女æ§ãèªåã®éœåã«åãããŠé£çšããŠããŸãããšãéã«ç·æ§ã匷èŠãããã¯éšããŠå¥³æ§ã«æçšãããããšãªã©ãèããããŸãã
çµæãšããŠããç·æ¥é¿åŠè¬ïŒã¢ãã¿ãŒãã«ïŒã®ãªã³ã©ã€ã³èšºçã§ã®åŠæ¹ãã«ã€ããŠã¯ãäŸå€ãšããŠèªããããããšãšãªããŸããã
â 倧åå
ç·æ¥é¿åŠãèŠãã女æ§ãé©åãªå»çæ©é¢ã«ããããããã«ãããããçžè«çªå£ãå°åããšã«èšçœ®ããããããå»çæ©é¢ã玹ä»ããŠå¯Ÿé¢èšºçã«ã€ãªãä»çµã¿ãæ§ç¯ããã
ã女æ§ã®å¥åº·ã«é¢ããçžè«çªå£ã
âŒå¥³æ§å¥åº·æ¯æŽã»ã³ã¿ãŒ
âŒå©Šäººçžè«æ
âŒæ§ç¯çœªã»æ§æŽå被害è
ã®ããã®ã¯ã³ã¹ãããæ¯æŽã»ã³ã¿ãŒ
  çžè«ã®ãããèŠå¯ãšé£æºããŠããå»çæ©é¢ãå蚺ããå Žåãã¢ãã¿ãŒãã«ã«ãããèªå·±è² æ
ããŒãã«ãªã婿å¶åºŠãããããã§ãã®ã§ãææã¡ã®ãéããªããŠãäžåºŠçžè«ããŠã¿ãããšã倧åã§ãã
â¡ã©ããã人ã察象ã«ãªãã®ãïŒ
ïŒïŒè¿é£ã«å¯Ÿé¢èšºçå¯èœãªå»çæ©é¢ããªãå Žå
ïŒïŒå¥³æ§ã®å¥åº·ã«é¢ããçžè«çªå£çã®å»åž«ïŒé£æºå»åž«ãå«ãïŒãã女æ§ã®å¿ççãªç¶æ
ãéã¿ãŠã察é¢èšºçãå°é£ããšå€æããå Žå
äž»ã«ãã®ïŒãã¿ãŒã³ã該åœããŸãã
â¢ç£å©Šäººç§å»ãŸãã¯ååŽçæå®ã®ç ä¿®ãåè¬ããå»åž«ããäŸå€çã«å蚺ãããªã³ã©ã€ã³èšºçãè¡ãïŒ1é ã®ã¿ã®é¢å€åŠæ¹ïŒ
â£ç ä¿®ãåããè¬å€åž«ã«ãã調å€ãåããè¬å€åž«ã®é¢åã§å æãã
â»å»åž«ãšè¬å€åž«ã¯ãã確å®ãªé¿åŠæ³ãé©åã«èª¬æããå蚺è
ãã3é±éåŸã«ç£å©Šäººç§å»ã«ããçŽæ¥ã®å¯Ÿé¢èšºçãåããããšã確å®ã«æ
ä¿ãã
æç« ãšããŠæžããšå°ããããã«ããã§ãããå³åŒåãããšããããããã§ãã

ç»åïŒçè·roo!
ç»åãã¿ãŠãããããšæããŸãããåŠæ¹ã®ããŒãã«ãäžããããã®ãªã³ã©ã€ã³èšºçã ã£ãã¯ãããã©ãããŠãçµæ§ãªããŒãã«ãæããŠããŸããŸããäžæ£å©çšãé²ãããã«ã¯å¿ èŠãªããšãããããŸãããé£ããã§ããã
ãã®ãªã³ã©ã€ã³èšºçã«ã€ããŠèª¿ã¹ãŠãããšããã¹ãã«ãããšãããã«ãã¢ãã¿ãŒãã«ããªã³ã©ã€ã³èšºçïŒLineã®ãããªãããšãïŒã§åŠæ¹ããŠããããšãããµã€ãã«åºäŒããŸããã
ïŒïŒç·æ¥é¿åŠè¬ã«ã¯ã©ããã£ããã®ãããã®ãïŒ
ç·æ¥é¿åŠè¬ãšããŠäœ¿çšãããè¬ã«ã¯ã©ããã£ããã®ãããã®ã§ããããïŒ
è¬ã®äœçšãçè§£ããããã«ã¯ããŸãæçµåšæãç¥ãå¿
èŠããããŸãã
ãã®äžåŠCollegeã®ç»åãããããããã£ãã®ã§èŒããŠãããŸãã

FSHïŒåµèåºæ¿ãã«ã¢ã³
LHïŒé»äœåœ¢æãã«ã¢ã³
LHãµãŒãžïŒLHã®æ¿åºŠã®æ¥æ¿ãªé«ãŸã
ãç·æ¥é¿åŠè¬ã®äœçšæ©åºã¯ã¯ã£ãããšã¯ããã£ãŠããªãããã§ãããåºæ¬çã«ã¯ãé»äœãã«ã¢ã³ãè¶³ããŠãããšããèŠåºäžéšïŒè³ïŒãžã®ä¿¡å·ãéãããšã§é»äœåœ¢æãã«ã¢ã³ïŒLHïŒã®åæ³ãæå¶ïŒLHãµãŒãžãæå¶ïŒããåµåã®æçãšæåµãé»å®³ããããšã«å ããŠãLHãµãŒãžãé
ãããåãããããŸãã
ãã®ã»ãã«ããå粟é»å®³äœçšïŒåå®®é žç®¡ç²æ¶²ã®ç²æ§å¢å ïŒãå粟åµçåºé»å®³äœçšïŒåå®®å
èã®è²èåïŒãèããããŠããŸãã
6.1 ã¬ããã«ã²ã¹ãã¬ã«ïŒLNGïŒ
è¬äŸ¡åºæºåèŒåã®å»è¬åã§ã¯ãããŸããããçŸå𿥿¬åœå ã§ãã®äœ¿çšãèš±å¯ãããŠããå»è¬åã¯ãã¬ããã«ã²ã¹ãã¬ã«ïŒLNGïŒã®ã¿ã§ãã®ã§ããã®æåãäžå¿ã«ã¿ãŠãããããšæããŸãã
æååïŒã¬ããã«ã²ã¹ãã¬ã«
ãã«ã¬ãé 1.5mg®ïŒããã補è¬/æŠç°è¬åïŒïŒå
çºå
ã¬ããã«ã²ã¹ãã¬ã«é 1.5mgãFã®ïŒå¯å£«è£œè¬ïŒïŒåŸçºå

äŸ¡æ Œã¯èªè²»èšºçã®ãããå»çæ©é¢ãè¬å±ã«ãã£ãŠç°ãªããŸãã
aïŒ ã¬ããã«ã²ã¹ããªã«ïŒLNGïŒãšäœé
ã¬ããã«ã²ã¹ãã¬ã«ïŒLNGïŒã«é¢ããŠè峿·±ãæç®ããããŸãããäœéãšLNGã®æçšéã«é¢ãããã®ã§ãã
Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing,Contraception,94(1),52-7,2016(PMIDÂ 27000996 )
BMIæ£åžžè
ãšè¥æºè
ã§ãè¬ç©åæ
ïŒPKïŒã«å·®ããããã©ãããã¿ããã®ã§ããBMIæ£åžžè
ïŒBMI=äžå€®å€22.8ïŒ20.8-23.7ïŒïŒ5åïŒïŒè¥æºè
ïŒBMI=39.5ïŒ35.946.7ïŒïŒïŒåïŒã®åèšïŒïŒåãªã®ã§ãµã³ãã«æ°ãšããŠã¯å°ãªãæ°ãšãªã£ãŠããŸãã

çµæã¯ãã®ããã«ãªã£ãŠããŠãæ£åžžBMI女æ§ã«1.5mgã®éåžžéãæäžããå Žåãšãè¥æºå¥³æ§ã«3mgã®éåžžã®åéãæäžããå Žåã®è¬ç©åæ ãè¿äŒŒããŠããŸããã
ããªãã¡ãè¥æºå¥³æ§ãæ£åžžBMI女æ§ãšåã广ãåŸãããã«ã¯ãåã®éãæçšããªããŠã¯ãããªããšããããšã«ãªããŸããããã®BMI39.5ãšããæ°åã¯ãäŸãã°èº«é·155cmã®äººã§ããã°äœé95kgãããã®äººã該åœããã®ã§ããªããªã該åœãã人ãå°ãªãã®ããªãšããå°è±¡ã§ãã
ããäžã€åããããªæç®ããããŸãããããã ãšããå°ãè¥æºBMIã®èšå®ã¯äœããªã£ãŠããŸãã
Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index,Contraception,95(5):464-469,2017(PMIDÂ 28126541 )
æ£åžžBMI女æ§ïŒå¹³åBMIïŒ22.0ïŒç¯å²18.8ïœ24.6ïŒ16å
è¥æºBMI女æ§ïŒå¹³åBMIïŒ34.3ïŒç¯å²30.6ïœ39.9ïŒ16å
ã¬ããã«ã²ã¹ãã¬ã«ïŒLNGïŒã®è¬ç©åæ
ïŒPKïŒãæ¯èŒïŒäž»èŠè©äŸ¡ïŒAUC0-24ã®çŸ€éå·®ã®æ¯èŒïŒ
LNGæçšåŸã®å¹³åAUC0-24ããã³æå€§æ¿åºŠïŒCmaxïŒã¯ãBMIæ£åžžå¥³æ§ããè¥æºBMI女æ§ã®æ¹ã50ïŒ
äœãã£ãïŒAUC0-24 100.8 vs. 208.5ng*h/mLãp<0.01ãCmax 10.8 vs. 18.2ng/mLãp=0.01ïŒ
ãã¡ãã®çµæã§ãè¥æºå¥³æ§ã§ã¯åã®æäžéãå¿ èŠããã§ãã
é¿åŠæ³äœ¿çšã«é¢ããWHOå»åŠé©çšåºæºïŒç¬¬5çã2015ïŒã®ãªãã§ãã
ECPã«ã€ããŠã¯ãBMIã25kg/m2æªæºã«æ¯ã¹ãŠ30kg/m2以äžã®å¥³æ§ã§é¿åŠå¹æãäœããªã
ãšèšèŒãããŠããŸãã
bïŒ ã¬ããã«ã²ã¹ããªã«ïŒLNGïŒã®æçšã¿ã€ãã³ã°
ã§ããã ãæ©ãæ®µéã§æçšããããšã§åŠåš 黿¢çãé«ããªãããšãããæ§äº€åŸ72æé以å
ã«ã§ããã ãéããã«ãLNGããæçšããå¿
èŠããããŸãã
æ°åã ãã§èãããšããã®æ¥ã®ãã¡ã«å蚺ããå¿ èŠããããšãèšããŸãïŒ24æé以å ã§åŠåš 黿¢ç95%ïŒã
ç·æ¥é¿åŠæ³ã®é©æ£äœ¿çšã«é¢ããæéïŒæ¥æ¬ç£å©Šäººç§åŠäŒç·š
Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998; 352: 428-433

72æéãè¶ ããŠ120æéãŸã§ã¯ããçšåºŠå¹æããããšãããŠããŸããã72æéãè¶ ããå Žåã«ã¯ãé ä»å IUDïŒåå®®å é¿åŠå ·ïŒãšã®äœµçšãæšå¥šãããŸãã
Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study,Contraception. 2016 ;93(6):526-32.(PMIDÂ 26944863 )
ãã®è³æã®äžã®æ£è å èš³ã¯ãã¡ãã®ããã«ãªããŸãã48æéãè¶ ããŠããã®äœ¿çšæ£è ãããŸãããç·æ¥é¿åŠå€±æçã¯0%ãšãªã£ãŠããŸãã
䜿çšã®åæãåŸãããã°ãLNGåç¬ããã广ãé«ããšèšãããŠããŸãã

cïŒå¯äœçšçºçŸç
äžãšåãæç®ïŒLancet 1998; 352: 428-433ïŒã§å¯äœçšçºçŸçãã¿ããã®ã§ãã

åŸæ¥ããçšããããŠããã€ããæ³ïŒYuzpeæ³ïŒãšæ¯ã¹ããšãLNGæçšã«ããå¯äœçšçºçŸçã¯äœãã§ãããæ¯èŒçé«ãé »åºŠã§ã¿ãããŠããŸãã
ããããã€ã³ã¿ãã¥ãŒãã©ãŒã ã®æ
å ±ãèŠããšãããŸã§å¯äœçšé »åºŠãé«ããªããæ·»ä»ææžäžã§ã¯æªå¿ã»ååãé »åºŠäžæã«åé¡ãããŠããŸãã
dïŒã¬ããã«ã²ã¹ããªã«ïŒLNGïŒæçšåŸã«æ³šæãã¹ãããšïŒïŒé±éåŸã®å蚺ã¯ãªãå¿ èŠãïŒïŒ
ãããããç·æ¥é¿åŠæ³ã®é©æ£äœ¿çšã«é¢ããæéïŒæ¥æ¬ç£å©Šäººç§åŠäŒç·šãã®äžã«èšèŒããããŸãã
LNGã®æçšãæåµé
å»¶ãæãããšãããã®ã§ã次åæçµãŸã§ã¯ãLNGãæçšããç¿æ¥ãã 21 æ¥éããããã¯åŠåš ãæ©ãã«åŠå®ãããå Žåã«ã¯ 14 æ¥é çµå£é¿åŠè¬ïŒOCïŒãæçšããããªã©ããŠããã¡ããšé¿åŠããããã«æå°ããã
Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial,Lancet. 2002;360(9348):1803-10.(PMIDÂ 12480356 )

衚ã§ã¿ããšãLNGæçšåŸã«æ§è¡çºããã£ã人ã§ã¯ãåŠåš 黿¢çãäœäžããŠããããšãããããŸããLNGã¯æçšã«ãããã®åŸã®é¿åŠå¹æãããè¬ã§ã¯ãªããããæçšããããšãèªèŠãæã£ãæ éãªè¡åãå¿ èŠã§ãã
ãŸããåŠåš 黿¢ãæåãããåŠãã¯æçµãããŠã¯ãããŠããããŸãããLNGæçšåŸã®èº«äœã¯éåžžã®ãã«ã¢ã³ãã©ã³ã¹ãšã¯ç°ãªã£ãŠããŸã£ãŠããããããã€æçµããããã¯ããããŸããã
ãããã®ããšãå«ããŠã®ïŒé±éåŸã®ãã©ããŒãšå®ããããŠãããããïŒé±éåŸã®å蚺ããšãŠãéèŠã§ãã
ãŸã3é±éåŸã®å蚺ã¯ãããããã®é¿åŠã«å¯Ÿããæ£ããç¥èãäŒãããšããæå³ã§ã倧åã§ãã
6.2 ãŠãªããªã¹ã¿ãŒã«é ¢é žãšã¹ãã«ïŒUPAïŒ
ãŠãªããªã¹ã¿ãŒã«é
¢é
žãšã¹ãã«ïŒella®ïŒã¯ãæ¥æ¬ã§èªå¯ãããŠããå»è¬åã§ã¯ãªãããå人茞å
¥ãããã¯åãæ±ãã®ããç
é¢ã§åŠæ¹ããŠãããããšãå€ãããã§ãã
åœå
ã§ã¯ã ãªãªãµã«å ããã iDrugStore ããšãã£ããšãããæåã§ããããã茞å
¥åã®ãããå±ããŸã§ã«ã¯æ©ããŠãïŒïœïŒïŒæ¥ã¯ããããŸãã
åäººèŒžå ¥ã«é¢ããŠã¯åŸè¿°ããŸãããèªå·±è²¬ä»»ãšããéšåãã€ããå¯äœçšãåºãå Žåã®åœã®ææžæªçœ®ããªãããšããçºéããå°çãŸã§æéããããããšãªã©ãããããããã¯ã§ããŸããã

æåµåã®æéãšLHãµãŒãžïŒé»äœåœ¢æãã«ã¢ã³æ¿åºŠã®é«ãŸãïŒãå§ãŸã£ãåŸã®äž¡æ¹ã§æåµãé
ããããšèšãããŠããŸãã
ãŠãªããªã¹ã¿ã«ã¢ã»ããŒãïŒUPAïŒãšã¬ããã«ã²ã¹ãã¬ã«ïŒLNGïŒãæ¯èŒãã詊éšã®ããŒã¿ããããŸãã
Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis,Lancet. 2010;375(9714):555-62.( )
å¯Ÿè±¡ïŒæ§äº€ãã5æ¥ä»¥å
ã«æ¥å±ããæ£è
2221人
ãŠãªããªã¹ã¿ãŒã«ã¢ã»ããŒã30mgïŒn=1104ïŒãŸãã¯ã¬ããã«ã²ã¹ãã¬ã«1.5mgïŒn=1117ïŒã«æ¯ãåããããã
äž»èŠè©äŸ¡ïŒæ§äº€ãã72æé以å
ã«ç·æ¥é¿åŠãåãã女æ§ã®åŠåš çã§æ¯èŒ
ãŠãªããªã¹ã¿ãŒã«ã¢ã»ããŒã矀ïŒ15äŸïŒ1.8ïŒ
ã95ïŒ
CI 1.0-3.0ïŒ
ã¬ããã«ã²ã¹ãã¬ã«çŸ€ïŒ22äŸïŒ2.6ïŒ
ã95ïŒ
CI 1.7-3.9ïŒ
ã¬ããã«ã²ã¹ããªã«çŸ€ã®æ¹ãåŠåš 黿¢çã¯äœãçµæãšãªã£ãŠããŸãã
æ§äº€åŸ72æéïœ120æéã®éã«ç·æ¥é¿åŠè¬ãåãã203人ã®å¥³æ§ã«ãããŠã3ä»¶ã®åŠåš ãããããã®ãã¹ãŠãã¬ããã«ã²ã¹ãã¬ã«çŸ€ã§ãã£ããšå ±åãããŠããŸãã
äœçšæ©åºãªã©ããèããŠããŠãªããªã¹ã¿ãŒã«ã¢ã»ããŒãã¯72æéãè¶ ããŠã®åŠåš 黿¢çãé«ããšèšãããŠããŸãã
6.3 ããã§ããªã¹ãã³
ããã§ããªã¹ãã³ã¯æ¥æ¬ã§èªå¯ãããŠããå»è¬åã§ã¯ãããŸãããç±³åœé£åå»è¬ååºïŒïŒŠïŒ€ïŒ¡ïŒã§ã¯ãã€ã³ã¿ãŒããããå人茞å
¥ã«ããå
¥æãã¹ãã§ãªãå»è¬åã«ã€ããŠãç±³åœå
ã®æ¶è²»è
åãã«æ³šæåèµ·ãè¡ã£ãŠããŸãããããã§ããªã¹ãã³ã¯ããã«è©²åœããŠããŸãïŒåçåŽåçããŒã ããŒãžããïŒã
åäººèŒžå ¥ã§ã®ãã«ã®äœ¿çšã¯ããªãæ¹ãããïŒ
ãå»è¬åã驿£ã«äœ¿çšããã«ããããããèµ·ããå¯äœçšã«ããå¥åº·è¢«å®³è ã«å¯ŸããŠã¯ãå»è¬åå»çæ©åšç·åæ©æ§ïŒPMDAïŒãå¯äœçšææžçµŠä»ãè¡ããšãããŠããŸããããããŸã§ãåçåŽå倧è£ã®èš±å¯ãåããŠæ¥æ¬ã§åžè²©ãããŠããå»è¬åããããŠãããããæµ·å€ããèŒžå ¥ããè¬å€ã¯ææžã®å¯Ÿè±¡ãšã¯ãªããŸããã
ãŸããèªç±èšºçããä¿éºèšºçãããšããéšåã¯ãã®å¯äœçšææžå¶åºŠã«ã¯ããŸãé¢ä¿ããªããã驿£ãªäœ¿çšãããã§ãããšããã®ãé¿åŠç®çãã§äœ¿çšãããŠãããã倧åã«ãªã£ãŠããŸãã
6.4 ã€ããæ³ïŒYuzpeæ³ïŒ
ãšã¹ããã²ã³ãšããã²ã¹ãã³ã®äž¡æ¹ãå«ãçµå£é¿åŠè¬ã®ä»£æ¿æäžæ³ïŒYuzpeæ³ïŒã§ããæ¥æ¬ã§ã¯ãã©ãããŒã«Â®ãšããåååã§çºå£²ãããŠããã1é äžãã«ã²ã¹ãã¬ã«0.5mgããšããã«ãšã¹ãã©ãžãªãŒã«0.05mgå«ãŸããŠããŸãã

æç𿹿³ãšããŠã¯ãæ§äº€æž72æé以å ã«2é æçšãããã®12æéåŸã«å床2é æçšãããã®ã§ãã
ã¬ããã«ã²ã¹ããªã«ã®ãšããã§è§ŠããŸããããåŠåš 黿¢çã§æ¯èŒãããšå¹æãä»äžã€ã®ããã«å¯äœçšã¯åŒ·ãåºããããä»ã«ææ®µããªãå Žåã«ã¯äœ¿çšããããšããããšæããŸãããæããããäœ¿çšæ¹æ³ãæ®ã£ãŠãããšããæãã¯åŠããŸããã
ãããã«
è²ã 調ã¹ãŠããŸãããã婊人ç§é åã¯å¥¥ãæ·±ããªãšãããããŠæããããããŸããããããããå°ããã€å匷ããªãããã®èšäºã«å ããŠãããã°ãšæã£ãŠããŸãã
ã100ïŒ åŠåš ãåé¿ã§ããããã§ã¯ãªãããšããããšãæ£è ããã«äŒããããšã倧åã ãšæããŸãã
ä»åè²ã 調ã¹ãŠããäžã§å©ç£åž«ããããã£ãŠããYoutubeãè²ããªäºãåãäžããŠããŠå匷ã«ãªããŸãããâ
ãè¬å€åž«ãç·æ¥é¿åŠè¬ãæž¡ãéã®ç¢ºèªäºé
ã
âæ¬äººã§ããããšã身åèšŒææžã§ç¢ºèªãã
âçŸåšåŠåš ããŠããªãããš
ïŒåŠåš åæã»äžæã«æäžããå Žåã«ã¯ã女æ§èå
ã®å€æ§åšã®ç·æ§ååã¯ç·æ§èå
ã®å¥³æ§åãèµ·ããããšããããã確èªããïŒ
âæä¹³äžã§ãããã©ãã
ïŒLNGã¯æä¹³äžã«ç§»è¡ããããã24æéã¯æä¹³ãããããšãããŠããããïŒ
âæçµæ§äº€ãã72æé以å
ã§ããããš
âé»äœãã«ã¢ã³ã®ã¢ã¬ã«ã®ãŒããªã
â䜵çšè¬ã確èªãã
ïŒä»£è¬é
µçŽ CYP3A4èªå°è¬ãšã®äœµçšã§ã¯å¹ææžåŒ±ãèµ·ããããšãããããïŒ
説æå
容
âåŠåš ã100ïŒ
åé¿ã§ããããã§ã¯ãªã
âåæ°ãåºãããšã¯ããããååã¯å°ãªãã
ã2æé以å
ã«ååããå Žåã¯å床å
æããå¿
èŠãããã
âæè¬åŸã«æ§äº€ãéå§ããããé¿åŠå¹æã¯äœäžãã
ïŒæåµãé
ãããŠããã ããªã®ã§ãé
ããæåµæã«æ§äº€ããããšããã§åŠåš ããŠããŸãããšãããããïŒ
â€ã©ãããŠãåŸ
ãŠãªãå Žåã¯ãç¿æ¥ããOCïŒäœçšéãã«ïŒãæçšãã
âåŠåš ã®å¯èœæ§ïŒç°ææ§åŠåš ãå«ãïŒã®å¯èœæ§ã«å¯Ÿãã3é±éåŸã«åŠåš åå¿æ€æ»ãç£å©Šäººç§å蚺ããããã
ïŒåŠåš ããŠããªããã°ãæ°æ¥ããæé·ïŒé±éçšåºŠåŸã«æçµãèµ·ããããïŒ
âæ£ããé¿åŠæ¹æ³ã«ã€ããŠã話ãã
ïŒãªãºã æ³ãè£å€å°ç²Ÿãªã©ã¯é¿åŠæ¹æ³ã«å«ãŸããªãããšããŸãã話ãã³ã³ããŒã ã«ã€ããŠã倱æçã¯10æ°ïŒ
ãã確å®ã§ã¯ãªããäœçšéãã«ãé¿åŠåšå
·ãçšããé¿åŠæ¹æ³ãèæ
®ããããšãææ¡ïŒ
æçš
â1é ãç®ã®åã§æçšããŠããã
æãŸãªãç¶æ³ã§æŽåçã«æ§è¡çºãè¡ãããã®ã§ã¯ãªãããšã確èªããããæŽåçãªç¶æ³ã§ããã°ãå°åã®æ§æŽåæ¯æŽã»ã³ã¿ãŒã®é£çµ¡å ãäŒããã
ãç ä¿®ãåè¬ããè¬å€åž«ã»è¬å±ã®ãªã¹ãã
åçåŽåçã®ããŒã ããŒãžã«æ²èŒäºå®
Coming soon....